
Sahajanand Medical Technologies' ₹475.48 crore initial public offering (IPO) opened for public subscription today, October 15, 2026, with a price band of ₹327 to ₹344 per share. As of 10:18 A.M. on the first day of bidding, the issue had been subscribed 0.02 times.
The IPO will remain open until October 19, 2026. The allotment status is expected to be finalised on October 21, 2026. Following this, the company's shares are provisionally set to debut on the BSE and NSE on October 23, 2026.
The expected IPO schedule is as follows:
|
Event |
Date |
|
Subscription Opening Date |
15 October 2026 |
|
Subscription Closing Date |
19 October 2026 |
|
Basis of Allotment Date |
21 October 2026 |
|
Refund Initiation Date |
22 October 2026 |
|
Credit of Shares |
22 October 2026 |
|
Listing on BSE and NSE |
23 October 2026 |
Note: The allotment and listing dates are tentative and may be revised.
Explore other Upcoming IPOs on BSE and NSE.
[October 15, 2026, 10:18 A.M.]
|
Category |
Subscription (x) |
|
Qualified Institutional Buyers (QIBs) |
0.00x |
|
Non-Institutional Investors (NIIs) |
0.02x |
|
Retail Individual Investors (RIIs) |
0.03x |
|
Employees |
0.00x |
|
Total |
0.02x |
Established in 2001, Sahajanand Medical Technologies is an R&D-focused medical device manufacturer specialising in products for vascular and structural heart procedures. Its portfolio includes coronary stents and balloons, transcatheter aortic valve implantation (TAVI) devices, occluders, renal stents and peripheral drug-coated balloons (DCBs).
The company’s products reached 77 countries in FY2026 and 65 countries during the three months ended June 30, 2026, including India.
|
Particulars |
For the three month period ended June 30, 2026 (in ₹ crore) |
FY26 (in ₹ crore) |
FY25 (in ₹ crore) |
|
Revenue from operations |
351.67 |
1,210.50 |
1,024.88 |
|
EBITDA |
48.58 |
170.65 |
128.02 |
|
Profit After Tax (PAT) |
15.09 |
69.08 |
25.15 |
Disclaimer: This news is solely for educational purposes. The securities/investments quoted here are not recommendatory.
To read the RA disclaimer, please click here